Advertisement

Topics

FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic ...

11:50 EDT 7 Aug 2017 | BioMedReports - Blog

Meets Primary Endpoint with Statistical Significance

Management to discuss results on today’s quarterly financial results conference call

SAN FRANCISCO, Aug. 07, 2017 (GLOBE NEWSWIRE)

Read more...

Original Article: FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic ...

NEXT ARTICLE

More From BioPortfolio on "FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic ..."

Quick Search
Advertisement